ATXI
Avenue Therapeutics, Inc.NASDAQHealthcare$0.35-17.11%ClosedMarket Cap: $1.1M
As of 2026-04-04
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
0.50
P/S
0.66
EV/EBITDA
0.59
DCF Value
$20.40
FCF Yield
-198.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
-219.6%
Net Margin
-207.2%
ROE
-89.8%
ROA
-99.2%
ROIC
-168.3%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $0.00 | $-709.0K | $-0.21 |
| FY 2025 | $1.4M | $-2.9M | $-0.93 |
| Q3 2025 | $0.00 | $-683.0K | $-0.21 |
| Q2 2025 | $1.4M | $335.0K | $0.11 |
Analyst Ratings
View AllConsensus
Buy
Target (Consensus)
$12.00
Target (Median)
$12.00
Target Range
$12.00 - $12.00
1 Strong Buy0 Buy0 Hold0 Sell0 Strong Sell
Trading Activity
Insider Trades
View AllFortress Biotech, Inc.10 percent owner
SellTue Jan 06
Fortress Biotech, Inc.10 percent owner
SellWed Apr 02
Fortress Biotech, Inc.10 percent owner
SellFri Jan 03
Herskowitz Neildirector
SellTue Dec 03
KRANZLER JAY Ddirector
SellThu Nov 07
Company Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
-0.62
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.